168 related articles for article (PubMed ID: 20069338)
1. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors.
Burris HA; Jones SF; Williams DD; Kathman SJ; Hodge JP; Pandite L; Ho PT; Boerner SA; Lorusso P
Invest New Drugs; 2011 Jun; 29(3):467-72. PubMed ID: 20069338
[TBL] [Abstract][Full Text] [Related]
2. Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.
Gomez HL; Philco M; Pimentel P; Kiyan M; Monsalvo ML; Conlan MG; Saikali KG; Chen MM; Seroogy JJ; Wolff AA; Escandon RD
Anticancer Drugs; 2012 Mar; 23(3):335-41. PubMed ID: 22123335
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.
Blagden SP; Molife LR; Seebaran A; Payne M; Reid AH; Protheroe AS; Vasist LS; Williams DD; Bowen C; Kathman SJ; Hodge JP; Dar MM; de Bono JS; Middleton MR
Br J Cancer; 2008 Mar; 98(5):894-9. PubMed ID: 18319713
[TBL] [Abstract][Full Text] [Related]
4. A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study.
Souid AK; Dubowy RL; Ingle AM; Conlan MG; Sun J; Blaney SM; Adamson PC
Pediatr Blood Cancer; 2010 Dec; 55(7):1323-8. PubMed ID: 20712019
[TBL] [Abstract][Full Text] [Related]
5. A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose.
Holen KD; Belani CP; Wilding G; Ramalingam S; Volkman JL; Ramanathan RK; Vasist LS; Bowen CJ; Hodge JP; Dar MM; Ho PT
Cancer Chemother Pharmacol; 2011 Feb; 67(2):447-54. PubMed ID: 20461380
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.
Lee CW; Bélanger K; Rao SC; Petrella TM; Tozer RG; Wood L; Savage KJ; Eisenhauer EA; Synold TW; Wainman N; Seymour L
Invest New Drugs; 2008 Jun; 26(3):249-55. PubMed ID: 17962907
[TBL] [Abstract][Full Text] [Related]
7. First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors.
LoRusso PM; Goncalves PH; Casetta L; Carter JA; Litwiler K; Roseberry D; Rush S; Schreiber J; Simmons HM; Ptaszynski M; Sausville EA
Invest New Drugs; 2015 Apr; 33(2):440-9. PubMed ID: 25684345
[TBL] [Abstract][Full Text] [Related]
8. A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors.
Infante JR; Kurzrock R; Spratlin J; Burris HA; Eckhardt SG; Li J; Wu K; Skolnik JM; Hylander-Gans L; Osmukhina A; Huszar D; Herbst RS
Cancer Chemother Pharmacol; 2012 Jan; 69(1):165-72. PubMed ID: 21638123
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
[TBL] [Abstract][Full Text] [Related]
10. A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma.
Hollebecque A; Deutsch E; Massard C; Gomez-Roca C; Bahleda R; Ribrag V; Bourgier C; Lazar V; Lacroix L; Gazzah A; Varga A; de Baere T; Beier F; Kroesser S; Trang K; Zenke FT; Klevesath M; Soria JC
Invest New Drugs; 2013 Dec; 31(6):1530-8. PubMed ID: 24077982
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
[TBL] [Abstract][Full Text] [Related]
12. Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.
Jones R; Vuky J; Elliott T; Mead G; Arranz JA; Chester J; Chowdhury S; Dudek AZ; Müller-Mattheis V; Grimm MO; Gschwend JE; Wülfing C; Albers P; Li J; Osmukhina A; Skolnik J; Hudes G
Invest New Drugs; 2013 Aug; 31(4):1001-7. PubMed ID: 23329066
[TBL] [Abstract][Full Text] [Related]
13. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
Chao J; Synold TW; Morgan RJ; Kunos C; Longmate J; Lenz HJ; Lim D; Shibata S; Chung V; Stoller RG; Belani CP; Gandara DR; McNamara M; Gitlitz BJ; Lau DH; Ramalingam SS; Davies A; Espinoza-Delgado I; Newman EM; Yen Y
Cancer Chemother Pharmacol; 2012 Mar; 69(3):835-43. PubMed ID: 22105720
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
Sewak S; Sorich J; O'Leary J
Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
[TBL] [Abstract][Full Text] [Related]
15. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.
Fox E; Aplenc R; Bagatell R; Chuk MK; Dombi E; Goodspeed W; Goodwin A; Kromplewski M; Jayaprakash N; Marotti M; Brown KH; Wenrich B; Adamson PC; Widemann BC; Balis FM
J Clin Oncol; 2010 Dec; 28(35):5174-81. PubMed ID: 21060028
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors.
Holen K; DiPaola R; Liu G; Tan AR; Wilding G; Hsu K; Agrawal N; Chen C; Xue L; Rosenberg E; Stein M
Invest New Drugs; 2012 Jun; 30(3):1088-95. PubMed ID: 21424701
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer.
Tsimberidou AM; Akerley W; Schabel MC; Hong DS; Uehara C; Chhabra A; Warren T; Mather GG; Evans BA; Woodland DP; Swabb EA; Kurzrock R
Mol Cancer Ther; 2010 Dec; 9(12):3410-9. PubMed ID: 21159616
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck.
Tang PA; Siu LL; Chen EX; Hotte SJ; Chia S; Schwarz JK; Pond GR; Johnson C; Colevas AD; Synold TW; Vasist LS; Winquist E
Invest New Drugs; 2008 Jun; 26(3):257-64. PubMed ID: 18038218
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors.
Gordon MS; Ilaria R; de Alwis DP; Mendelson DS; McKane S; Wagner MM; Look KY; LoRusso PM
Cancer Chemother Pharmacol; 2013 Jan; 71(1):21-7. PubMed ID: 23228983
[TBL] [Abstract][Full Text] [Related]
20. Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.
Shimizu T; LoRusso PM; Papadopoulos KP; Patnaik A; Beeram M; Smith LS; Rasco DW; Mays TA; Chambers G; Ma A; Wang J; Laliberte R; Voi M; Tolcher AW
Clin Cancer Res; 2014 Oct; 20(19):5032-40. PubMed ID: 25107918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
